SCHEMBL10040552

SCHEMBL10040552

Cc1ccc(OC(=O)N2CCC(c3nnc(-c4ccc(F)cc4)o3)CC2)cn1

nearest known ligand 0.53

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.53
TNKS O95271 3/20 0.43
PARP1 P09874 3/20 0.43
PARP2 Q9UGN5 2/20 0.43
POLB P06746 1/20 0.43
TP53 P04637 4/20 0.41
FAAH O00519 3/20 0.41
HDAC3 O15379 1/20 0.41
CYP2C9 P11712 1/20 0.41
HDAC1 Q13547 1/20 0.41
HDAC6 Q9UBN7 1/20 0.41
GPR119 Q8TDV5 1/20 0.41
KCNH2 Q12809 1/20 0.40
MCHR1 Q99705 1/20 0.40
PDK2 Q15119 1/20 0.40
GRM5 P41594 1/20 0.39
KMT2A Q03164 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10040543 0.90 MAPT (0.52) MAPTTNKSPARP1PARP2POLB
SCHEMBL10040638 0.90 MAPT (0.51) MAPTTNKSPARP1PARP2POLB
SCHEMBL1652158 0.86 GPR119 (0.45) MAPTPOLBTP53FAAHCYP2C9
SCHEMBL1653169 0.86 MAPT (0.52) MAPTTNKSPARP1PARP2POLB
SCHEMBL10040554 0.83 MAPT (0.49) MAPTTNKSPARP1PARP2POLB
SCHEMBL10040553 0.83 MAPT (0.51) MAPTTNKSPARP1PARP2POLB
SCHEMBL10040562 0.82 SMN1; SMN2 (0.46) FAAHGPR119KMT2A
SCHEMBL1653017 0.82 GPR119 (0.42) MAPTTP53FAAHGPR119KMT2A
SCHEMBL10040555 0.82 LMNA (0.55) MAPTPOLBGRM5KMT2A
SCHEMBL10040632 0.80 MAPT (0.49) MAPTTNKSPARP1PARP2POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8207199-B2 Azole compound ASTELLAS PHARMA INC. (JP) 2012-06-26 US disclosed
US-8207199-B2 Azole compound ASTELLAS PHARMA INC. (JP) 2012-06-26 US disclosed
US-20110118311-A1 AZOLE COMPOUND ASTELLAS PHARMA INC. (JP) 2011-05-19 US disclosed
US-20110118311-A1 AZOLE COMPOUND ASTELLAS PHARMA INC. (JP) 2011-05-19 US disclosed
EP-2308869-A1 AZOLE COMPOUND Astellas Pharma Inc. (JP) 2011-04-13 EP disclosed
WO-2010007966-A1 AZOLE COMPOUND アステラス製薬株式会社 (JP) 2010-01-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110118311-A1 AZOLE COMPOUND FAAH, FAAH2, TRPV1 MAPT 2507/4885TNKS 753/4885PARP1 3227/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.